15/06/2020 - 14:49

Proteomics achieves clinical validation for kidney test

15/06/2020 - 14:49

Bookmark

Save articles for future reference.

A major clinical study involving 3,000 patients has validated ASX-listed Proteomics’ “PromarkerD” predictive test for diabetic kidney disease with the study confirming that PromarkerD has a high probability of predicting a clinical decline in kidney function up to four years in advance of it actually happening. With the major milestone achieved, Proteomics is now looking to commercialise the technology in the USA.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options